ArticleJournal of biological engineering2026
CIRCLE-F/V: a dual-mode CRISPR-Cas13a cascade biosensor for ultrasensitive and visual detection of low-abundance EGFR mutations.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Precise identification of low-frequency EGFR L858R mutations is crucial for targeted therapy and prognosis in non-small cell lung cancer (NSCLC). Here, we present CIRCLE-F/V (CRISPR-based Integrated Restriction-assisted Cyclic Loop-mediated Enhancement Fluorescence/Visual platform), a dual-mode CRISPR-Cas13a cascade biosensor enabling ultrasensitive and specific mutation detection through integrated fluorescence and visual readouts. The system combines restriction-assisted mutant enrichment with cyclic CRISPR signal amplification. Genomic DNA is selectively digested with MscI to eliminate wild-type alleles, followed by T7 promoter–mediated PCR amplification and in vitro transcription. The resulting RNA activates Cas13a-crRNA complexes, initiating both direct reporter cleavage and dumbbell-triggered cascade amplification (DTCA) -mediated secondary signal enhancement. Under optimized conditions, the fluorescence mode achieved a variant allele frequency (VAF) sensitivity of 0.01%, with an estimated genomic DNA detection limit of ~ 3.6 fM in the integrated workflow and an RNA detection limit of ~ 2.16 pM. By replacing the fluorescent reporter with a FAM–biotin probe, the visual mode via lateral flow strips was realized with a VAF sensitivity of 0.01%. Clinical validation demonstrated complete concordance with next-generation sequencing (NGS), accurately classifying as high-, low-, and negative mutation samples. By integrating selective allele enrichment, cyclic amplification, and dual-mode readout, CIRCLE-F/V represents a sensitive, versatile, and clinically adaptable platform for rapid EGFR genotyping and early NSCLC screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.